- Research article
- Open Access
- Open Peer Review
Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme
© Hakkaart-van Roijen et al.; licensee BioMed Central Ltd. 2013
- Received: 13 April 2012
- Accepted: 23 August 2013
- Published: 30 September 2013
There is an 80% prevalence of two or more psychiatric symptoms in psychogeriatric patients. Multiple psychiatric symptoms (MPS) have many negative effects on quality of life of the patient as well as on caregiver burden and competence. Irrespective of the effectiveness of an intervention programme, it is important to take into account its economic aspects.
The economic evaluation was performed alongside a single open RCT and conducted between 2001 and 2006. The patients who met the selection criteria were asked to participate in the RCT. After the patient or his caregiver signed a written informed consent form, he was then randomly assigned to either IRR or UC.
The costs and effects of IRR were compared to those of UC. We assessed the cost-utility of IRR as well as the cost-effectiveness of both conditions. Primary outcome variable: severity of MPS (NPI) of patients; secondary outcome variables: general caregiver burden (CB) and caregiver competence (CCL), quality of life (EQ5D) of the patient, and total medical costs per patient (TiC-P). Cost-utility was evaluated on the basis of differences in total medical costs). Cost-effectiveness was evaluated by comparing differences of total medical costs and effects on NPI, CB and CCL (Incremental Cost-Effectiveness Ratio: ICER). CEAC-analyses were performed for QALY and NPI-severity. All significant testing was fixed at p<0.05 (two-tailed). The data were analyzed according to the intention-to-treat (ITT)-principle. A complete cases approach (CC) was used.
IRR turned out to be non-significantly, 10.5% more expensive than UC (€ 36 per day). The number of QALYs was 0.01 higher (non-significant) in IRR, resulting in € 276,290 per QALY. According to the ICER-method, IRR was significantly more cost-effective on NPI-sum-severity of the patient (up to 34%), CB and CCL (up to 50%), with ICERs varying from € 130 to € 540 per additional point of improvement.
No significant differences were found on QALYs. In IRR patients improved significantly more on severity of MPS, and caregivers on general burden and competence, with incremental costs varying from € 130 to € 540 per additional point of improvement. The surplus costs of IRR are considered acceptable, taking into account the high societal costs of suffering from MPS of psychogeriatric patients and the high burden of caregivers. The large discrepancy in economic evaluation between QALYs (based on EQ5D) and ICERs (based on clinically relevant outcomes) demands further research on the validity of EQ5D in psychogeriatric cost-utility studies. (Trial registration nr.: ISRCTN 38916563; December 2004).
- Economic evaluation
- Nursing home
- Cognitive impairment
- Neuropsychiatric symptoms
In psychogeriatric patients who suffer from cognitive impairment or dementia, there is an 80% prevalence of two or more psychiatric symptoms, e.g. depression, anxiety, paranoia, aggression [1, 2]. Multiple psychiatric symptoms (MPS) have many related negative effects on the quality of life of the patients as well as on caregiver burden and competence [1, 3, 4]. Psychotropic drugs, e.g. (a) typical antipsychotics, are widely used to treat the MPS in usual nursing home care, despite their limited effects and potentially harmful side-effects [5, 6]. Reports in the literature indicate that psychotherapeutic treatment may be effective for individual psychiatric symptoms . However, psychotherapeutic interventions that focus on MPS are complex, due to the multiple nature of MPS in combination with cognitive disorders, somatic co-morbidity, and social problems. Furthermore, our literature search did not reveal any large-scale, comprehensive randomized controlled (RCT) studies on integrative psychotherapeutic programmes in nursing homes [8, 9]. For these reasons, we developed a unique integrative psychotherapeutic nursing home programme: integrative reactivation and rehabilitation (IRR) . The IRR-programme was aimed at psychogeriatric patients who were at high risk for admission to a nursing home. Limits on health-care resources mandate that resource-allocation decisions are guided by considerations of costs in relation to expected benefits. In cost-effectiveness analysis, the ratio of net health-care costs to net health benefits provides an index by which priorities may be set. Quality-of-life concerns are commonly incorporated in the calculation of health benefits as adjustments to life expectancy . The incremental cost-effectiveness ratio (ICER) is the ratio of the estimated difference between the costs of two interventions and the estimated difference between the outcomes of these two interventions. Cost-effectiveness studies are mainly used to facilitate informed decision making about interventions that are both more costly and more effective than their comparator. The performed RCT was designed to test the (cost-effectiveness) of IRR on MPS of psychogeriatric patients as well as on burden and competence of the caregiver. The primary analyses concerned the mean differences between IRR and the usual multidisciplinary nursing home care (UC) on continuous data of the outcome variables. The results of this analysis are published elsewhere . IRR had a significant and moderate to large surplus effect (up to 34%) on reducing the MPS of psychogeriatric patients. In fact, at six-month follow-up there was a total reduction up to 46% in number and 61% in severity. Furthermore, at the end of the treatment IRR had a large surplus effect (up to 36%) on reducing caregiver burden. During the follow-up the surplus effect even increased up to 50%, while UC showed almost no effect. Irrespective of their effectiveness, the economic aspect of treatment programmes, i.e. an economic evaluation from a societal perspective, is also important . The costs and effects of IRR were compared to those of UC. We assessed the cost-utility of IRR as well as the cost-effectiveness of both conditions on three outcome variables.
In the urban region of Nieuwe Waterweg Noord (NWN), near Rotterdam in the Netherlands, the patients were referred from an (ambulant) mental health service (5.4%), a general hospital (13.8%), a memory clinic (6%) and by general practitioners or primary healthcare services (75.1%). Before inclusion in the randomized controlled trial, all patients underwent a comprehensive assessment. The inclusion criteria were: 1) Diagnostic and Statistical Manual (DSM IV) classification of dementia, amnestic disorders or other cognitive disorders; 2) age: ≥65 years; 3) psychiatric symptoms: Neuropsychiatric Inventory (NPI) 3 or more symptoms; 4) cognitive functioning: Mini Mental Status Examination (MMSE) ≥18 and ≤27 as well as Barthel Index (BI) ≥5 and ≤19, and 5) informed consent. The exclusion criteria were: 1) delirium; 2) life-threatening somatic co-morbidity; 3) active compulsory admission regime (according to psychiatric legislation), and 4) insufficient command of the Dutch language.
The economic evaluation was performed alongside an open Randomised Controlled Trial (RCT), conducted between 2001 and 2006. Included patients were randomly and blindly assigned to either IRR or UC, using a randomisation algorithm. In the first half of the study the assignment ratio was 1 (IRR):2 (UC). However, due to the limited number of eligible patients, time restrictions and financial limitations, this was reversed to 2 (IRR):1 (UC) in the second half of the study. We ultimately included 168 patients (81 IRR and 87 UC). 'Multiple psychiatric symptoms of the patient’ was the primary outcome variable, and 'Burden’ and 'Competence’ of the caregiver were secondary outcome variables. For the economic evaluation we collected the data of direct medical costs of the patient. The outcome variables were assessed at T1 (within two weeks after intake) and at T3 (follow-up; six months after the conclusion of the three-month intervention). Measurements of the costs were conducted every 8 weeks over the previous four weeks. The final measurement took place at 40 weeks. Data were collected by trained assessors who were not members of the Intervention team. Assessors were not blind to the intervention. This study was approved by the Medical Ethics Review Committee (METC) of the Erasmus University Medical Centre.
Interventions were provided mainly in a group setting, but also individually when necessary. On average patients received treatment for five functional psychiatric problems, provided by four disciplines; sometimes a discipline used more than one type of intervention. The availability of a wide range of interventions made it possible to provide a highly individualized package of interventions. After multidisciplinary consultation, the psychogeriatrician - a nursing home physician with experience in psychiatric treatment - prescribed the interventions for each functional problem. Staff members were trained to systematically conduct the IRR programme. Monitoring took place weekly during the course of the personal intervention plan and was guided by the method of standardized goal attainment scaling (GAS: score range 1 to 7; 7 = independent (no help needed) . Each discipline provided a written GAS score, based on functional progress during the therapy sessions. These scores were discussed in the multidisciplinary meeting, without the patients/caregivers, and a consensus GAS score was determined.
UC consisted of a relatively high level of nursing home care. This care is provided by a multidisciplinary team. In this study, UC was provided in the following settings: at home (n=22; 25.3%), at home with mental healthcare (out-reaching) or psychogeriatric day care/treatment (n=14; 15.7%), in an assisted living residence (n=6; 7.2%), and in a nursing home (n=45; 51.8%). The multidisciplinary UC staff consisted of a nursing home physician or social geriatric physician, a psychologist, a paramedical team (physiotherapist, occupational therapist, speech therapist, welfare worker) and a nursing team (Registered Nurses, Certified Nurse Assistants and/or Nurse Assistants). UC was provided by different types of core multidisciplinary teams, each working from a different, mostly emotion-oriented, theoretical framework.
We used two sets of instruments, one for the patient and caregiver, and one for the economic aspects. Multiple psychiatric Symptoms (MPS) of the patient was assessed by the Neuropsychiatric Inventory (NPI 12 item version: 'NPI-sum-severity’ : 0 to 144; 0 = no severity symptoms at all), administered to the caregiver . We chose the caregiver NPI, because the caregivers formed a stationary group from the moment of inclusion in the study until the end of the treatment and the six-month follow-up. Furthermore, they generally provide a better reflection of the actual needs, thoughts and feelings of dementia patients than the relatively discontinuous nursing teams can provide . General burden of the caregiver was assessed using the Caregiver Burden (CB: 0 to 100; 0=optimal) , and competence with the Caregiver Competence List (CCL: 28 to 112; 112=optimal) [4, 18]. MMSE was used to measure patient memory (0 to 30; 30=normal) , and self-care was assessed using the Barthel Index (BI) (0 to 20; 20=normal) . To assess the risk for being placed in a nursing home we used the Global Deterioration Scale (GDS: 1–7; 1 is normal) . Somatic co-morbidity was assessed using the International Classification of Diseases (ICD-10). The DSM IV disorders (axes I and II) were classified by a research psychiatrist. The following demographic data were collected: gender, age, marital status, family relation, residence, education level, income level and job employment.
For the economic evaluation, i.e. cost utility analysis, we assessed quality of life with EuroQol Health questionnaire (EQ5D) (-0.59 to 1.0; 1.0=optimal), administered to the patient . The EQ5D is a validated tool for measuring general health–related quality of life. EQ5D consists of five items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each having the rating options 'no problems’, 'some problems’ and 'extreme problems’. The health descriptions can be linked directly to empirical valuations of the general public, which allows utilities to be computed .
Costs were estimated by multiplying the use of health care by their corresponding unit prices. The number of days admitted to the nursing home was collected directly from the participating centres. The questionnaire Trimbos iMTA for Costs associated with Psychiatric illness (TiC-P), which asks about the number of health care contacts over the previous four weeks, was applied to collect data on all other use of health care from the patients. We used TiC-P to collect data on direct medical costs . Unit prices of the interventions for the year 2004 were estimated based on information provided by the financial department of Argos Zorggroep. Therefore, data on the direct (e.g. medical staff, nursing staff) and indirect costs (e.g. overhead, housing) of 2004 was used to calculate the unit costs per day for IRR and UC, respectively. All other health care utilisation was valued using their corresponding unit prices based on the Dutch manual for costing studies in Economic Evaluations . Unit prices of health care services for 2004 were adjusted to 2005 prices using the consumer price index (http://www.cbs.nl). So, all relevant health care costs were included.
The patient mean utility scores were estimated by applying the area-under-the curve method (AUC) . The data scores of patients who died were valued zero if the patient died in the first 4 weeks of a measurement period or in any of the consecutive measurement periods. If a patient died in the last 4 weeks of a measurement period we valued the data scores as missing, or the available scores of the measurement period in which the person died, and zero in the consecutive periods.
The cost-utility was evaluated by relating the difference in total direct medical costs per patient to the difference in terms of Quality Adjusted Life Years gained (QALY), which yielded a cost per QALY estimate. In addition, to estimate the cost effectiveness of IRR versus UC, we determined the Incremental Cost-Effectiveness Ratio (ICER) by comparing the two conditions on mean differences in total medical costs divided by mean differences in effects on NPI, CB and CCL, respectively . The estimated participation interval of dropouts (time in days participating in the study) was determined using a Cox-regression analysis. All significance testing was fixed at P<0.05 (two-tailed). The data were analyzed according to the intention to treat (ITT)-principle. The statistical analyses were performed with the software programmes SPSS, version 21, and SAS, version 9.2.
Characteristics of the study sample
General details of participants, distinguished by intervention
Age (in years), mean (SD)
Marital status: alone
Educational level: low
Domicile: at home
Primary caregiver: spouse
DSM-IV dementia, (axis-I), count (%):
Dementia of the Alzheimer’s type
Dementia due to other conditions
DSM-IV personality disorders (axis-II), count (%)
GDS-deterioration, mean (SD)
Somatic co-morbidity (ICD-10), mean (SD)
Nursing home days (LOS), mean (SD)
Age (in years), mean (SD)
Marital status: living together
Educational level: low
Level of outcome across time (T1 - T3) distinguished by intervention
T1 (baseline measurement)
T3 (six months follow-up)
= (+/-) *)
Psychiatric function disorders patient
0 to 144
Caregiver burden (CB)
0 to 100
28 to 112
Quality of life patient
-0.59 to 1.00
Mean direct medical costs (€) and mean QALY after 40 weeks for IRR and care as usual
Complete case analysis (CC)
Nursing home (incl. IRR)
Assisted living residence
Direct medical costs
At baseline, TiC-P and EQ5D data were available for 96% (n=161), and at 40 weeks follow-up for 38% (n=63) of the participants. Table 3 shows that the mean nursing home costs per patient (including the costs of IRR) were non-significantly higher in IRR than in UC. However, the costs of home care and day care were significantly lower in IRR. The mean costs in IRR were non-significantly (10.5%) higher (€ 3,205; 95% CI: 374.20 to 10153.20) than those in UC. This implies € 36 extra per IRR-treatment day (in total: average 90 days treatment duration). Moreover, the number of QALYs of the patients was non-significantly (0.01) higher in IRR (95% CI:-0.09 to 0.11), which resulted in a mean of € 275,000 per QALY.
Cost-effectiveness after 40 weeks; distinguished by Intervention; ICER-approach
Caregiver burden (CB)
Caregiver competence (CCL)
The cost-effectiveness acceptability curve (CEAC) illustrates the uncertainty surrounding the estimate of cost- effectiveness [28–32]. CEACs are intended to represent the uncertainty concerning the cost-effectiveness of a health-care intervention in the context of decision making involving two interventions as an alternative to confidence intervals around ICERs . Nowadays, use of CEACs has become widespread amongst others in the field of medicine [33–37].
The CEAC is based on the joint density of incremental costs (ΔC) and incremental effects (ΔE) for the intervention of interest (IRR), and represents the proportion of the density where the intervention is cost-effective for a range of values of λ. In our study, the CEAC is estimated by parametric bootstrapping of the distribution [28, 29, 31]. The CEAC is determined as the proportion of the (ΔC/ ΔE) points where the intervention is considered cost-effective .
The objective of this study was an economic evaluation of an Integrative Reactivation and Rehabilitation (IRR-) programme. IRR was focused on psychogeriatric patients who were at high risk for admission to a nursing home. We estimated the cost-utility (QALYs) and cost-effectiveness (ICERs) of IRR by comparing IRR to usual multidisciplinary nursing home care (UC). The cost-utility analysis (CUA) shows that the amount of QALYs for psychogeriatric patients was almost equal between IRR and UC, while the costs were 10.5% lower in UC. Overall, the costs per QALY for IRR were far higher than € 30,000 per QALY (€ 275,000 per QALY) which the Dutch National Council for public health and health care assumes to be the threshold for cost-effectiveness of sustainable and meaningful care (2006) . To test the sensitivity of the results for missing data we also applied the multiple imputation methodology, a technique commonly applied in economic evaluations [39, 40]. Using multiple imputation, total medical costs in IRR were significantly higher than in UC (€ 4.572,--; 95% Cl: 364.24 to 8797.76) and the number of QALYs was non-significantly lower (0.02; 95% CI: -0.09 to 0.05). So, this analysis supported the conclusion that IRR apparently is not cost-effective in terms of QALYs. Moreover, CEAC of QALYs suggests that, when the costs per patient around € 60,000 is acceptable, then the probability is 0.50 that the treatment (i.c. IRR) is considered cost-effective compared to UC.
In contrast, at six-month follow-up, the cost-effectiveness analysis in terms of ICERs showed significant surplus improvement of patients (up to 34%) and caregivers (up to 50%) in IRR. Surplus improvement of the patient on severity of multiple psychiatric symptoms was about € 320 per point. For the caregivers, the surplus improvement on general burden was about € 130 per point and on competence € 540. These are clinically relevant results because MPS of patients and caregiver burden are the two phenomena experienced as most problematic in dementia care . CEAC of MPS suggests that, when the costs per patient around € 600 is acceptable, then the probability is 0.50 that the treatment (i.c. IRR) is considered cost-effective compared to UC.
However, the cost-effectiveness results are not easily compared to cost-effectiveness of other health care interventions, because there is no reference value of costs per effect unit for these clinical outcomes. Hence, this type of information is of less value in health care policy decision making than costs per QALY.
The difference in results between QALYs and ICERs is remarkable. In terms of mean differences, the cost-effectiveness on clinically relevant outcomes, i.e. severity of psychiatric symptoms in psychogeriatric patients, caregiver burden and competence was relatively large and in favour of IRR [42, 43]. In contrast, the mean difference between the IRR and UC on the EQ5D was minor (0.04; 95% CI: -0.06 to 0.14), with only relatively small percentages of clinically relevant (≥ 0.5 SD) improved patients (IRR 24% vs. UC 15%) [12, 13]. This means that the EQ5D proved to be relatively unresponsive to change. This corresponds to the findings of Ballard et al. , who showed that clinically relevant improvement on Behavourial and Psychological Symptoms of Dementia (BPSD) had only small effects on general quality of life measurements. Completion of the EQ5D by proxy (i.e. the caregiver) may enhance the correlation between EQ5D and BPSD . All in all, this does not facilitate comparison of the effects of interventions in cost-utility studies in psychogeriatrics. Further research is urgently needed [45–48].
One of the strengths of this study was that it was based on a relatively large sample size of patients. Furthermore, it was possible to estimate the benefit of full participation as the relatively high percentage of dropouts did not differ significantly on the observed variables. The majority of dropouts could be ascribed to death, which was not significantly different between IRR and UC. The phenomenon of high dropout percentages is well known in geriatric research [5–7]. It basically reflects the vulnerability of the psychogeriatric patients suffering from MPS.
How can the results be interpreted within the context of the literature? They confirm that psychotherapeutic treatment, based on person-oriented and problem-solving principles, is effective in psychogeriatric patients [46, 48]. Moreover, the relative unresponsiveness of the patient’s EQ5D compared to the positive changes on the severity of MPS is in line with the results reported in literature [44–48]. Furthermore, as far as we know, our RCT-study was one of the first comprehensive studies in a nursing home setting with a relative large sample size to address integrative psychotherapeutic treatment of psychogeriatric patients and their caregivers [7, 9].
However, the study had some weaknesses. First of all, RCT was not blinded. In a clinical study like this, blinding is not feasible. As the research staff had to visit the patients and caregivers personally, they knew the intervention history of the patients. Although we trained the research staff to administer the assessment instruments, this was no guarantee that information bias was precluded. Whether bias emerged in favour of IRR is difficult to demonstrate. As the assessments at baseline showed only minor differences between IRR and UC, except for somatic co-morbidity, the information bias at baseline seems to be limited. Another weakness was that only direct medical costs of patients were available; any other costs, specifically costs related to informal care at home, had to be excluded. This may have led to an underestimation of costs at home, especially in UC. A third limitation was the absence of (medical) cost-data for the caregiver. Especially, the significantly large beneficial effects of IRR on carer burden and competence may have lowered their medical consumption. This means that the results of the economic evaluation suggest a probable underestimation of (cost-)effectiveness of IRR. Furthermore, the study ended at 40 weeks.
Regarding generalization of the findings of this RCT, it is important to keep in mind that 50% of the eligible patients refused to participate. A relatively large proportion of these patients lived with a spouse. However, post-hoc prognostic analysis showed that living together did not have any prognostic quality with respect to improvement on the primary outcome variable. In IRR the beneficial long-term effects on the patient and the caregiver confirm those mentioned in the literature [46, 48]. It is expected that by identifying the less effective therapeutic components and subsequently making them more effective or leaving them out, the cost-effectiveness of IRR may increase. Identification of and screening for those psychogeriatric patients and their caregivers with a relatively high likelihood of improving, presents another opportunity to increase the cost-effectiveness of IRR.
In terms of QALYs, IRR did not seem to be cost-effective as compared to UC. However, at six-month follow-up, fully participating patients and caregivers in IRR improved significantly more on the clinically relevant parameters, i.e. severity of psychiatric symptoms (up to 34%) as well as on caregiver burden (up to 50%). Furthermore, the surplus effect on the competence of caregivers was substantial. The incremental costs-effectiveness ratios varied from € 130 to € 540 per additional point of improvement, on the multiple psychiatric symptoms (MPS) of the patient and caregiver burden and competence respectively. The total medical costs were 10.5% higher in IRR. The large discrepancies between IRR and UC on QALYs and ICERs demand further research regarding EQ5D validation in intervention studies with psychogeriatric patients. Considering all available evidence, the surplus costs of IRR may be considered acceptable when taking into account the beneficial effects on the high societal costs of suffering from multiple psychiatric symptoms of psychogeriatric patients and high burden of caregivers. To optimize the cost-utility and cost-effectiveness of IRR, the development of a tool to identify suitable psychogeriatric patients and caregivers for IRR is of key clinical and economic importance. Such a tool would contribute to the optimization of medical decision making based on an economical evaluation. Future studies that include caregiver costs have to be performed to strengthen the evidence, preferably RCTs.
The authors wish to thank everyone who has helped them to write this manuscript. They especially thank Ingrid Middelburg for her secretarial assistance and dealing with revisions and Maggie Oattes for her helpful suggestions and careful editing of the final version of the manuscript.
No disclosures to report.
No pharmaceutical of industry support.
For this study a grant was received from The Netherlands Organisation for Health Research and Development (http://www.zonmw.nl), a national organization that promotes quality and innovation in the field of health research and health care, initiating and fostering new developments. The majority of ZonMw’s commissions come from the Ministry of Health, Welfare and Sport (VWS).
- Aalten P, De Vugt E, Jaspers N, Jolles J, Verhey FRJ: The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables. Int J Geriatr Psychiatry. 2005, 20 (6): 531-536. 10.1002/gps.1317.View ArticlePubMedGoogle Scholar
- Bakker TJEM, Duivenvoorden HJ, Van der Lee J, Trijsburg RW: Prevalence of psychiatric function disorders in psychogeriatric patients at referral to nursing home care: the relation to cognition, activities of daily living and general details. Dement Geriatr Cogn Disord. 2005, 20 (4): 215-224. 10.1159/000087298.View ArticlePubMedGoogle Scholar
- Black W, Almeida OP: A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. Int Psychogeriatr. 2004, 16 (3): 295-315. 10.1017/S1041610204000468.View ArticlePubMedGoogle Scholar
- Jansen APD, Van Hout HPJ, Van Marwijk HWJ, Nijpels G, Gundy C, Vernooij-Dassen MJFJ, de Vet HCW, Schellevis FG, Stalman WAB: Sense of competence questionnaire among informal caregivers of older adults with dementia symptoms: a psychometric evaluation. Clin Pract Epidemiol Ment Health. 2007, 3: 11-10.1186/1745-0179-3-11.View ArticlePubMedPubMed CentralGoogle Scholar
- Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007, 176 (5): 627-632. 10.1503/cmaj.061250. Correction for Schneeweiss et al. CMAJ. 2007; 176: 627–632View ArticlePubMedPubMed CentralGoogle Scholar
- Selbaek G, Kirkevold Ø, Engeldal K: The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes – a 12-month follow-up study. Am J Geriatr Psychiatry. 2008, 16 (7): 528-536. 10.1097/JGP.0b013e318167ae76.View ArticlePubMedGoogle Scholar
- Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG: Old age task force of the world federation of biological psychiatry, systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005, 162 (11): 1996-2021. 10.1176/appi.ajp.162.11.1996.View ArticlePubMedGoogle Scholar
- Bird M, Llewellyn-Jones RH, Korten A, Smithers H: A controlled trial of a predominantly psychosocial approach to BPSD: treating causality. Int Psychogeriatr. 2007, 19 (5): 874-891. 10.1017/S1041610206004790.View ArticlePubMedGoogle Scholar
- Logsdon RG, McCurry SM, Teri L: Evidence-based psychological treatments for disruptive behaviors in individuals with dementia. Psychol Aging. 2007, 22 (1): 28-36.View ArticlePubMedGoogle Scholar
- Bakker TJEM: Palliative care in chronic psychogeriatrics. A case-study. Patient Educ Couns. 2000, 41: 107-113. 10.1016/S0738-3991(00)00120-8.View ArticlePubMedGoogle Scholar
- Drummond MF, Sculpher MJ, Torrance GW: Methods for the economic health care programmes. 2005, Oxford: Oxford University PressGoogle Scholar
- Bakker TJEM, Duivenvoorden HJ, van der Lee J, Olde Rikkert M, Beekman ATF, Ribbe MW: Integrative psychotherapeutic nursing home programme to reduce multiple psychiatric symptoms of psychogeriatric patients and caregiver burden: a randomized controlled trial. Am J Geriatr Psychiatry. 2011, 19 (6): 507-520. 10.1097/JGP.0b013e3181eafdc6.View ArticlePubMedGoogle Scholar
- Cummings JL, Koumaras B, Chen M, Mirski D, Rivastigmine Nursing Home Study Team: Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005, 3 (3): 137-148. 10.1016/S1543-5946(05)80020-0.View ArticlePubMedGoogle Scholar
- Rockwood K, Joyce B, Stolee P: Use of Goal Attainment Scaling in measuring clinical important change in cognitive rehabilitation patients. J Clinical Epidemiol. 1997, 50: 581-588. 10.1016/S0895-4356(97)00014-0.View ArticleGoogle Scholar
- Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, et al: The neuropsychiatric inventory, comprehensive assessment of psychopathology in dementia. Neurology. 1994, 44: 2308-2314. 10.1212/WNL.44.12.2308.View ArticlePubMedGoogle Scholar
- Katona C, Livingston G, Cooper C, Ames D, Brodaty H, Chiu E: International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia. Int Psychogeriatr. 2007, 19 (3): 345-354. 10.1017/S1041610207005145.View ArticlePubMedGoogle Scholar
- van Exel NJ, Scholte op Reimer WJM, Brouwer WBF, van den Berg B, Koopmanschap MA, van den Bos GAM: Instruments for assessing the burden of informal caregiving for stroke patients in clinical practice: a comparison of CSI, CRA, SCQ and self-rated burden. Clin Rehabil. 2004, 18: 203-214. 10.1191/0269215504cr723oa.View ArticlePubMedGoogle Scholar
- Teunisse S: Dissertation. Clinimetrics in Dementia. 1997, University of AmsterdamGoogle Scholar
- Folstein MF, Folstein SE, McHugh PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.View ArticlePubMedGoogle Scholar
- de Haan R, Liburg M, Schuling J, Broeshart J, Jonkers L, van Zuylen P: Klinimetrische evaluatie van de Barthel-index, een maat voor beperkingen in het dagelijks functioneren [Clinimetric evaluation of the Barthel Index, a measure of limitations in daily activities]. Ned Tijdschr Geneeskd. 1993, 18: 917-921.Google Scholar
- Reisberg B, Ferris SH, De Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982, 139 (9): 1136-1139.View ArticlePubMedGoogle Scholar
- EuroQol Group: EuroQol – a new facility for measurement of health-related quality of life. Health Policy. 1990, 16: 199-208.View ArticleGoogle Scholar
- Essink-Bot ML, Stouthard MEA, Bonsel GJ: Generalizability of valuations on health states collected with the Euroqol questionnaire. Health Econ. 1993, 2: 237-10.1002/hec.4730020307.View ArticlePubMedGoogle Scholar
- Hakkaart-van Roijen L, Van Straten A, Donker M, et al: Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P). 2002, Rotterdam: iMTA, report number 02.61Google Scholar
- Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ. 1990, 300 (6710): 230-235.View ArticlePubMedPubMed CentralGoogle Scholar
- Suh GH: Health economics: basic principles and application in mental health. Int Psychogeriatr. 2007, 19 (6): 993-1002.View ArticlePubMedGoogle Scholar
- Muskens JB, Noy J, Verburg M: Progression of dementia and admission: an explorative longitudinal study. [ ] (Article in Dutch). Huisarts en wetenschap. 1992, 35: 490-496.Google Scholar
- Van Hout BA, Al MJ, Gordon GS, et al: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994, 3: 309-319. 10.1002/hec.4730030505.View ArticlePubMedGoogle Scholar
- Briggs A, Fenn P: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 1998, 7: 723-740. 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Briggs A, Gray A: Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999, 3: 2.Google Scholar
- Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001, 10: 779-787. 10.1002/hec.635.View ArticlePubMedGoogle Scholar
- O’Brien B, Briggs A: Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002, 11: 455-468. 10.1191/0962280202sm304ra.View ArticlePubMedGoogle Scholar
- Bower P, Byford S, Barber J, et al: Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses. Br Med J. 2003, 326: 1247-1250. 10.1136/bmj.326.7401.1247.View ArticleGoogle Scholar
- Byford S, Knapp M, Greenshields J, et al: Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a rational decision making approach. Psychol Med. 2003, 33: 977-986. 10.1017/S0033291703008183.View ArticlePubMedGoogle Scholar
- Haddock G, Barrowclough C, Tarrier N, et al: Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. Br J Psychiatr. 2003, 183.Google Scholar
- Scott J, Palmer S, Paykel E, et al: Use of cognitive therapy for relapse prevention in chronic depression: cost-effectiveness study. Br J Psychiatr. 2003, 182: 221-227. 10.1192/bjp.182.3.221.View ArticleGoogle Scholar
- McCrone P, Knapp M, Proudfoot J, et al: Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatr. 2004, 185: 55-62. 10.1192/bjp.185.1.55.View ArticleGoogle Scholar
- Raad voor de Volksgezondheid en Zorg (RVZ)/National Council for Public Health and Health Care: Sustainable and Meaningful Care [in Dutch: Zinnige en Duurzame Zorg]. 2006, The Netherlands: The HagueGoogle Scholar
- Rubin DB: Multiple imputation after 18+ years. J Am Stat Assoc. 1996, 91 (434): 473-489. 10.1080/01621459.1996.10476908.View ArticleGoogle Scholar
- Oostenbrink JB, Al MJ: The analysis of incomplete cost data due to dropout. Health Econ. 2005, 14: 763-776. 10.1002/hec.966.View ArticlePubMedGoogle Scholar
- NIVEL and the Alzheimer Foundation, fact sheet 2: Problems and needs in dementia caregivers. Results of the national programme in dementia care. [Problemen en wensen van mantelzorgers van mensen met dementie.] (Report in Dutch). 2007, Peeters J, van Beek S, Francke AGoogle Scholar
- Livingston G, Katona C: The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int J Geriatr Psychiatry. 2004, 19 (10): 919-925. 10.1002/gps.1166.View ArticlePubMedGoogle Scholar
- Demaerschalk BM, Wingerchuk DM: Treatment of vascular dementia and vascular cognitive impairment. Neurologist. 2007, 13 (1): 37-41. 10.1097/01.nrl.0000252919.46622.28.View ArticlePubMedGoogle Scholar
- Ballard C, Margallo-Lana M, O’Brien JT, James I, Howard R, Fossey J: Top cited papers in International Psychogeriatrics: 6a. Quality of life for people with dementia living in residential, and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. Int Psychogeriatr. 2009, 21 (6): 1026-1030. 10.1017/S1041610209990998.View ArticlePubMedGoogle Scholar
- Wimo A, Winblad B: Pharmacoeconomic outcomes. Trial designs and outcomes in dementia therapeutic research (pp. 250–258). Edited by: Rockwood K, Gauthier S. 2006, Abingdon: Taylor and FrancisGoogle Scholar
- Selwood A, Thorgrimsen L, Orrell M: Quality of life in dementia – a one-year follow-up study. Int J Geriatr Psychiatry. 2005, 20 (3): 232-237. 10.1002/gps.1271.View ArticlePubMedGoogle Scholar
- Vogel A, Mortensen EL, Hasselbalch SG, Andersen BB, Waldemar G: Patient versus informant reported quality of life in the earliest phases of Alzheimer’s disease. Int J Geriatr Psychiatry. 2006, 21 (12): 1132-1138. 10.1002/gps.1619.View ArticlePubMedGoogle Scholar
- Knapp M, Mangalore R: The trouble with QALYs. Epidemiol Psychiatr Soc. 2007, 16 (4): 289-293.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/13/370/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.